Efficient Payload Delivery by a Bispecific Antibody-Drug Conjugate Targeting HER2 and CD63.
de Goeij, Bart E C G; Vink, Tom; Ten Napel, Hendrik; Breij, Esther C W; Satijn, David; Wubbolts, Richard; Miao, David; Parren, Paul W H I.
Mol Cancer Ther
; 15(11): 2688-2697, 2016 11.
Artigo em Inglês | MEDLINE | ID: mdl-27559142
Phase I dose-escalation study of MEDI-573, a bispecific, antiligand monoclonal antibody against IGFI and IGFII, in patients with advanced solid tumors.
Leverage nonclinical development of bispecifics by translational science.
A new approach for generating bispecific antibodies based on a common light chain format and the stable architecture of human immunoglobulin G<sub>1</sub>.
An FDA oncology analysis of CD3 bispecific constructs and first-in-human dose selection.
Stable IgG-like bispecific antibodies directed toward the type I insulin-like growth factor receptor demonstrate enhanced ligand blockade and anti-tumor activity.
Bispecific Antibodies Against HIV.
A new bispecific antibody targeting non-overlapping epitopes on IGF2: design, in vitro characterization and pharmacokinetics in macaques.
Bispecific Antibodies as a Development Platform for New Concepts and Treatment Strategies.
An anti-CD3/anti-CLL-1 bispecific antibody for the treatment of acute myeloid leukemia.
A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects.